Edition:
United States

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

39.68USD
20 Sep 2018
Change (% chg)

$0.30 (+0.76%)
Prev Close
$39.38
Open
$39.70
Day's High
$40.50
Day's Low
$39.66
Volume
56,967
Avg. Vol
117,790
52-wk High
$46.12
52-wk Low
$24.32

Chart for

About

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the... (more)

Overall

Beta: --
Market Cap(Mil.): $1,470.02
Shares Outstanding(Mil.): 37.33
Dividend: --
Yield (%): --

Financials

  BOLD.OQ Industry Sector
P/E (TTM): -- 107.68 32.65
EPS (TTM): -2.63 -- --
ROI: -33.18 1.61 12.72
ROE: -34.50 0.32 14.84

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

May 16 2018

BRIEF-Audentes Therapeutics Reports Qtrly Loss Per Share $0.74

* AUDENTES THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Audentes Therapeutics CEO Matthew Patterson's 2017 Total Compensation Was $6.9 Million

* AUDENTES THERAPEUTICS INC SAYS CEO MATTHEW PATTERSON'S 2017 TOTAL COMPENSATION WAS $6.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KknZ9F) Further company coverage:

Apr 27 2018

Competitors

  Price Chg
Amicus Therapeutics, Inc. (FOLD.OQ) $12.62 +0.81
Sanofi SA (SASY.PA) €74.67 --

Earnings vs. Estimates